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The history of vaccination clearly demonstrates that vaccines have been highly successful
in preventing infectious diseases, reducing significantly the incidence of childhood diseases
and mortality. However, many infections are still not preventable with the currently avail-
able vaccines and they represent a major cause of mortality worldwide. In the twenty-first
century, the innovation brought by novel technologies in antigen discovery and formulation
together with a deeper knowledge of the human immune responses are paving the way for
the development of new vaccines. Final goal will be to rationally design effective vaccines
where conventional approaches have failed.
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INTRODUCTION
In the last century, vaccines demonstrated to be a successful and
effective medical intervention representing one of the most impor-
tant applications of immunology to prevent infectious diseases. A
landmark in the history of immunology is the experiment con-
ducted by Edward Jenner in 1796, when he demonstrated that
inoculation with pus from cowpox lesions was conferring protec-
tion against smallpox infection (1) providing an innovative contri-
bution to immunization and the ultimate eradication of smallpox
(2). Smallpox was one of the most severe human diseases, respon-
sible only in Europe for the death of more than 400,000 people
per year. In 1979, smallpox was eradicated through a global vac-
cine administration campaign. Jenner’s work was further refined
by Louis Pasteur, who artificially attenuated viruses for use in
vaccines and in 1885 developed the first rabies human vaccine.
He brought a breakthrough in the prevention and treatment of
infectious diseases by establishing the basis of vaccinology, mean-
ing the principle of isolation, inactivation, and administration of
disease causing pathogens. The Pasteur’s principles have allowed
the development of “first generation” vaccines based on whole
microorganism killed or live-attenuated (e.g., Bacillus Calmette
Guerin BCG, plague, pertussis, and smallpox) (3,4).
In the second half of twentieth century improvements and
innovation in mammalian cell culture technology led to the growth
of viruses and development of live attenuated “second genera-
tion” vaccines such as polio (Sabin oral), measles, rubella, mumps,
and varicella. More recently, the use of inactivated polio vac-
cine (Salk type) together with oral vaccine has almost eradicated
polio from the world thanks to global vaccination (5). In devel-
oped countries national immunization programs have drastically
reduced most of the viral and bacterial infections that tradition-
ally affected children. In May 2012, the 194 Member States of
the World Health Organization Assembly endorsed the global
vaccine action plan (GVAP) with the vision of delivering univer-
sal access to immunization, with at least 2–3 million lives saved
per year worldwide (http://www.who.int/immunization/global_
vaccine_action_plan/). Although traditionally developed vaccines
have been in the last century of unquestionable value, saving more
than 700 million cases of disease and more than 150 million deaths,
the conventional methods of vaccine design have some limitations.
For example, they could not be used to develop vaccines against
microbes that do not grow in vitro (e.g., Mycobacterium leper,
papilloma virus type 16 and 18). They do not provide broadly
protective vaccines against pathogens with antigenic hypervari-
ability (e.g., serogroup B meningococcus, HIV, HCV) or against
pathogens with an intracellular phase, causing infections that are
predominantly controlled by T cells, such as tuberculosis and
malaria (6). Finally, traditional approaches of vaccine develop-
ment can be very slow and time consuming, not allowing a rapid
response to the need of a new vaccine, as in case of an influenza
pandemic.
To overcome all these limitations, during the last 30 years new
technologies have been applied to vaccine development. Recom-
binant DNA, polysaccharide chemistry, and more recently reverse
vaccinology (RV), structural vaccinology, and synthetic RNA vac-
cines are opening up the view for the designing and development
of “third generation” vaccines, previously defined as impossible to
make (Figure 1).
POLYSACCHARIDE CHEMISTRY AND GLYCO-CONJUGATE
VACCINES
One of the major immunological problems faced in the devel-
opment of polysaccharide vaccines has been their low immuno-
genicity especially in children below 2 years of age, who repre-
sent the main target population of vaccination (7, 8). Bacterial
polysaccharides are made of repeated monosaccharides linked
together by glycosidic linkages. Their multiple identical anti-
genic epitopes cross-link multiple membrane immunoglobulins
on a B cell to allow activation without the help of T cells (9).
Polysaccharides cannot be processed and presented to T-helper
cells and because of the lack of T-cell help, there is no germi-
nal center reaction and the associated isotype switching, avidity
maturation of the B cell receptors and induction of memory
B cells.
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FIGURE 1 |Technologies for vaccine development. Empirical approaches
consisting mostly of killed or live-attenuated microorganisms, partially
purified components of pathogens (subunit vaccines), detoxified toxins or
polysaccharides have represented the starting point in vaccinology, leading
to the successful elimination of many devastating diseases. During the last
30 years, several novel technologies such as recombinant DNA technology,
glyconjugation, reverse vaccinology, and structural vaccinology are opening
the possibility of designing new vaccines previously considered impossible
to make. Adapted from Rappuoli et al. (68).
Vaccines composed of plain bacterial polysaccharides have been
introduced since the 1970s to control diseases caused by Neisseria
meningitidis, Streptococcus pneumoniae, and Haemophilus influen-
zae type b (Hib) (10–12). However, these vaccines were poorly
immunogenic in infants >2 years of age and did not appear to
provide herd immunity, which is now recognized as a key element
to prevent invasive bacterial infections in children. To improve
immunogenicity of plain polysaccharides, they were chemically
conjugated to protein carriers such as tetanus toxoid (TT), diph-
theria toxoid (DT), and a non-toxic cross-reacting mutant of
DT (CRM197) (13). Glyco-conjugate vaccines activate B cells via
engagement of the B cell receptor following polysaccharide bind-
ing, processing of the protein carrier by polysaccharide-specific B
cells, and presentation of the resulting peptides or glycopeptides
in association with MHC class II molecules to T-helper cells. The
MHC class II-restricted cognate interaction between B and T cells
provides the costimulatory signals to B cells to start the germi-
nal center reaction with somatic hypermutation and class-switch
recombination generating B cells that will secrete high-avidity
IgG antibody against the polysaccharide antigen (14, 15). As a
consequence, vaccination with protein–polysaccharide conjugate
vaccines is able to induce a long last immune response, with high
affinity IgG antibodies and with the capacity to be boosted by sub-
sequent immunizations (14, 16, 17). Protein–polysaccharide con-
jugate vaccines were introduced in the 1980s against H. influenzae
type b (Hib) (18–20) inducing a better and persistent antibody
response in all age groups. Today, different strategies to prepare
conjugate vaccines can be used and effective glyco-conjugate vac-
cines are available for S. pneumoniae and the strains A, C, W, and
Y of N. meningitidis (meningococcal meningitis) (21, 22). These
vaccines are highly immunogenic and brought a huge reduction of
bacterial infections in those countries that have introduced them
into their immunization schedules (23–25). Although the progress
made in the technology of glyco-conjugate vaccines made pos-
sible the successful control of different bacterial infections, this
approach could not be applied to develop N. meningitidis type B
(MenB) vaccine. MenB is a major cause worldwide of meningi-
tis and sepsis, two devastating diseases that can kill children and
young adults within hours (26). It is a gram-negative bacterium
part of the commensal flora that colonizes the upper respiratory
tract of healthy individuals. In a small proportion of cases, the
bacterium can invade the host bloodstream and, after crossing the
blood–brain barrier, causes meningitis (27, 28). The unsuccess-
ful attempt of developing a MenB vaccine based on its capsular
polysaccharide was largely due to the fact that it is identical to the
polysialic acid present in human glycoproteins such as N-CAM.
Many efforts were directed toward the development of a protein-
based vaccine, all frustrated by the inconsistency of the protection
data probably due to the extreme variability of the known surface
proteins tested as vaccine antigens.
REVERSE VACCINOLOGY
A major revolution in vaccine discovery is linked to the advent of
genome sequencing technologies that have changed the landscape
in the slowly evolving field of vaccinology. Turning point was the
publication in 1995 of the genome sequence of the first living
organism (29). By sequencing the genome and by determining the
whole antigenic repertoire of the infectious organism, several can-
didate protective targets could be identified and tested for their
suitability as vaccine. The method, named Reverse Vaccinology
(RV), has provided a change in the perspective of vaccine design.
The idea of the RV was originated to overcome the problems
faced to develop an efficacious vaccine against MenB. The genome
sequencing of the MenB virulent strain MC58 (30) allowed to
select from the genomic data potential vaccine targets (31). The
principle at the basis of the RV approach was that successful vac-
cine targets were proteins either exposed on the surface of the
pathogen or secreted into the extracellular milieu. Starting from
2,158 encoded proteins bioinformatics analysis predicted that over
600 were either surface exposed or secreted. Of these, 350 were
cloned in Escherichia coli, expressed and used to immunize mice.
The sera of immunized animals were screened in a bactericidal
assay that is known to correlate with protection. At each step can-
didates not satisfying quality criteria were discarded; the process
led to the identification of previously unknown vaccine candi-
dates. Through this process three protective antigens that are
common to multiple MenB strains have been identified (fHbp,
NadA, and NHBA) and combined with a MenB outer membrane
vesicle (OMV) resulting in the first universal vaccine against MenB
(32). This is the first vaccine based on RV that has recently received
a positive opinion from the European Medicines Agency and has
been approved with the commercial name of Bexsero®. Following

























































Finco and Rappuoli Effective vaccines for the future
the success of the MenB project, the RV approach has been applied
to a variety of other important pathogens, such as S. pneumoniae
(33, 34), Streptococcus pyogenes (35), Chlamydia pneumonia (36),
Chlamydia trachomatis (37), Streptococcus agalactiae (38), E. coli
(39), and Leishmania major (40). Thus, the genome-based RV
strategy can provide innovative solutions for the design of vac-
cines difficult or even impossible to develop using conventional
methods (41).
NEXT GENERATION TECHNOLOGIES FOR VACCINE DESIGN
Novel technologies currently under investigation represent the
most valuable tools to be applied in vaccinology and could be
used today for addressing the medical needs of the twenty-first
century. Despite decades of efforts and investigation, satisfactory
vaccines have not yet been developed against several of the most
life-threatening infections, including tuberculosis, malaria, and
HIV, which claim the lives of more than 4 million people world-
wide each year. The high levels of variability of their antigenic
proteins and the required induction of both humoral and cellu-
lar immune responses have not allowed us to use conventional
vaccinology methods as successful strategies. The advent of a new
approach, named structural vaccinology, could represent today
a valid revolutionary alternative leading in the next years to an
efficacious vaccine design. Through the combination of human
immunology, structural biology, and bioinformatics knowledge,
antigenic epitopes are identified based on the protein amino acid
sequences and the resulting secondary and tertiary structures. The
principle is based on the observation that an efficacious immune
response does not require the recognition of the entire antigenic
protein, but the recognition of multiple selected epitopes might be
sufficient to induce protective immunity (42). Progresses in tech-
nologies aimed at interrogating the human B cell repertoire are
providing for the first time the possibility of isolating broadly neu-
tralizing antibodies targeting relevant conserved epitopes (43–45).
A deeper characterization of the crystal structure of an antigen in
complex with protective antibodies represents the launching point
for immunogen design to select relevant epitopes from a vaccine
standpoint. Once identified they can be expressed in a recom-
binant form and in an immunodominant fashion to be used as
potent immunogens (Figure 2). Recently, the group of Kwong et al.
(46) using a structure-based approach designed an immunogen
for respiratory syncytial virus (RSV) that elicits higher protective
responses than the postfusion form of the fusion glycoprotein,
which is one of the current leading RSV vaccine candidates enter-
ing clinical trials. Importantly, highly protective responses were
elicited in both mice and macaques. Structural vaccinology com-
bined with human immunology are therefore rapidly emerging
as a powerful alternative strategy for the rational design of engi-
neered vaccines bearing multiple antigenic epitopes offering the
opportunity of developing broadly effective immunity (47–49).
Another challenge in vaccinology is due to the limited capacity
of the immune system to develop potent and sustained antibody
responses at the extremes of age. Several studies in the last decades
have shown that antigen exposure in early life results in blunted,
delayed, or undetectable antibody responses to infections and
immunizations (50, 51). Effective IgG responses in infants require
several doses of vaccine, and to avoid a rapid wane of the titers
FIGURE 2 | New technologies aimed at interrogating the human B cell
repertoire after vaccination or infection are providing for the first time
the possibility of isolating broadly neutralizing antibodies that target
relevant conserved epitopes. A structural characterization of an antigen in
complex with protective antibodies represents the launching point for the
design of new immunogens bearing selected relevant protective epitopes
to be used for vaccination.
booster doses might be required after the first year of life. At the
other extreme of age, a significant decline in the capacity to induce
protective antibody titers is observed in individuals of 65 years
or older. The discovery of new adjuvants that help in eliciting
the appropriate sustained antibody response represents a valuable
strategy to overcome age-related hypo-responsiveness to vaccina-
tion. MF59 is an oil-in-water emulsion potent vaccine adjuvant
licensed in more than 20 countries for more than 13 years for use
in an influenza vaccine focused on elderly subjects. Recently, MF59
has been shown to be safe also in a seasonal influenza vaccine given
to infants and children, providing an increase in vaccine efficacy
from 43 to 89% (52, 53). However, in the last years increased
knowledge of the molecular mechanisms underlying the immune
response is leading to the discovery of molecules that can trig-
ger the immune system modulating antigen-specific immunity.
Monophosphoryl lipid A (MPL) is known to be a highly spe-
cific agonist of the toll-like receptor 4 (54). MPL adsorbed onto
aluminum salts has been included in the formulation of the AS04-
adjuvanted HPV-vaccine, the first example of a toll-like receptor
agonist to be licensed as part of a vaccine for human use (55).
As MPL other newly discovered innate immune receptor agonists
might be ideal molecules to be exploited as adjuvants for next gen-
eration vaccines aimed at improving immunogenicity mainly in
extreme ages.
Finally, together with the above described technologies used
to design new protective antigens and to optimally present them
to the immune system, also the new synthetic methods of vaccine
production are driving the development of the twenty-first century
vaccines. Nucleic acid-based vaccines represent a key advancement
in combining the benefits of in situ expression of antigens, with the
safety of inactivated and subunit vaccines. They might represent
a valuable tool to overcome problems encountered when design-
ing vaccines against pathogens that require a protective immunity
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mediated not only by antibodies but also by T cells. Up to now the
success rate of vaccine development decreases with the decreas-
ing ability of antibodies to confer protective immunity. A large
body of literature suggests that cytotoxic T cells are important in
protection from infectious diseases, such as tuberculosis, malaria,
and AIDS. This would require the creation of vaccines able to
induce strong T-cell responses, a weakness for existing vaccine
approaches. The evidence that CD8+ T cells can control infec-
tions comes mainly from HIV. Given the failure to protect using
the antibody-based gp120 vaccines (56, 57) T-cell-based vaccines
have been widely tested in non-human primates (58) demonstrat-
ing to be promising. Nevertheless an HIV prime/boost vaccine
based on adenovirus vector delivering T-cell epitopes failed to
protect patients from disease, and had little impact on viral load
(59). It is possible that this result may represent a proof-of-concept
that pure T-cell vaccines are not a solution for preventive vac-
cines. However, there remains a need for vaccines to protect against
infections for which antibodies are not sufficient or against non-
infectious diseases such as cancer or autoimmunity, where also
T cell immunity plays a critical role in conferring protection.
DNA based vaccines showed to be very promising in animals,
but in humans the magnitude of the immune response was lower
than that observed with conventional vaccines. To overcome these
limitations, approaches as DNA delivery by electroporation and
stimulation of the immune system via the use of genetic adju-
vants (i.e., in situ expression of immunologically active molecules
encoded by the DNA vaccine) have been used in human clinical
trials with encouraging preliminary results (60, 61). RNA vaccines
represent a valid alternative over DNA vaccines. They are based
on mRNA and self-amplifying RNA replicons that when injected
intramuscularly in mice result in local production of an encoded
reporter protein (62) and induction of immune responses against
the encoded antigen (63). RNA vaccines have several advantages
compared to DNA vaccines. RNA would eliminate the issue of
possible integration of plasmid DNA into the genome of the
immunized host, and it is translated directly in the cytoplasm
(64). It has not been clearly elucidated the mechanisms utilized by
RNA vaccines to induce an immune response, but it is likely that
expression and presentation of encoded antigens follow rules sim-
ilar to DNA vaccines. The efficiency and stability of RNA-based
vaccines have been increased through the use of viral-particle
engineered to express a heterologous antigen in place of the viral
structural genes. RNA vaccines, particularly self-amplifying repli-
cons, have therefore the potential of capturing the advantages of
both DNA vaccines and viral delivery while overcoming the draw-
backs of each technology. These favorable observations, supported
by preclinical proof-of-concept in animal tumor models, have led
mRNA vaccines into human clinical trials as immunotherapeutics
in metastatic melanoma and renal cell carcinoma patients (65)
showing to be able to elicit antigen-specific immune responses
(both antibodies and T cells). Clinical trials have also been per-
formed with RNA replicon vaccines packaged in viral particles
encoding for cytomegalovirus (CMV) gB and pp65/IE1 proteins.
The vaccine has shown to be well tolerated and immunogenic
in healthy CMV seronegative volunteers, with the added value of
inducing also CD8+ T-cell responses (66). The future of the RNA
vaccines will rely on the formulation with new synthetic delivery
systems to combine the effectiveness of live attenuated vaccines,
an equal or better safety profile than plasmid DNA vaccines, and
completely synthetic methods of manufacture.
Improvements in the synthetic vaccines research have provided
a unique tool to rapidly respond to the need of vaccine avail-
ability in case of flu pandemics. Dormitzer et al. have developed
a synthetic approach to generate vaccine viruses from sequence
data (67). Starting from the available hemagglutinin (HA) and
neuraminidase (NA) gene sequences, a cell-free gene assembly
technique has allowed rapid, accurate gene synthesis. Viral RNA
expression constructs encoding HA and NA and plasmid DNAs
encoding viral backbone genes were used to transfect Madin–
Darby canine kidney (MDCK) cells, qualified for vaccine man-
ufacture. Viruses for use in vaccines were rescued from MDCK
cells with increased yield of the essential vaccine antigen, HA.
The implementation of synthetic vaccine seeds has demonstrated
the capability of accelerating the response to influenza pan-
demics reducing the time required for vaccine manufacturing from
months to weeks.
CONCLUDING REMARKS
In conclusion, the last 30 years have represented a turning point
in vaccinology. New technologies such as recombinant DNA,
polysaccharide chemistry, and more recently RV, structural vac-
cinology, and synthetic RNA vaccines have greatly improved the
efficiency of the vaccine-target identification, selection, and devel-
opment process. Continuous progresses will be made in the
twenty-first century to design new vaccines that will become the
most efficient life insurance of the modern society, contributing
significantly to a disease-free long life.
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